**016 YOUNG PATIENTS WITH HEART FAILURE OFTEN DO NOT HAVE MAJOR ECG ABNORMALITIES**

A Mahmood,* 1M C Petrie, 2C Wong, 1A P Davie, 1University of Glasgow, Glasgow, UK; 2Golden Jubilee National Hospital, Glasgow, UK

**Background** It is commonly held that a normal ECG rules out the diagnosis of heart failure; however this has only been demonstrated in the elderly. Do young people with heart failure always have major ECG abnormalities?

**Aim** To determine the proportion of patients aged below 65 who had heart failure with LVSD who present with ECGs without major abnormalities.

**Methods** 100 consecutive admissions to the Scottish National Advanced Heart Failure Service at the Golden Jubilee National Hospital, Glasgow who were aged below 65 and had an echocardiogram and ECG available. Ejection fraction was quantified using the Simpson’s biplane method. ECGs were independently assessed by two cardiologists blinded to the result of the echocardiograms. Any disagreements were resolved by a third cardiologist. Majorly abnormal ECGs contained ≥1 of: Q-waves, left ventricular hypertrophy (LVH), bundle branch block and atrial fibrillation. Presence of Q waves was assessed subjectively by the two assessors and then using criteria as defined by the Universal Definition of Myocardial Infarction by a third assessor. Similarly the presence of LVH was assessed subjectively and using the Sokolow-Lyon Index. Minor abnormalities of ECG included atrial enlargement, bradycardia, tachycardia, broadening of QRS complex, poor R wave progression, left or right axis deviation, myocardial ischaemia, first degree atrioventricular block, and non-specific ST-T wave changes.

**Results** Of 100 consecutive patients, 77 were males and 23 females. Mean age was 50 years (range 18–64). 76 had major ECG abnormalities. 22 had only minor ECG abnormalities and no major ECG abnormalities; two had no abnormalities. All patient groups had marked LV systolic dysfunction (ejection fractions of 28.6% ±2.8, 28.4% ±3.4, 25.5% ±6.9 for those with major, minor and no abnormalities on ECG respectively). Analysis by criteria for Q waves demonstrated 71 had major ECG abnormalities, 27 had minor ECG abnormalities and 2 had none. Analysis by criteria for LVH gave the same results as the initial cardiological analysis.

**Conclusion** Only 71%–76% of patients under the age of 65 have major ECG abnormalities, compared to 98% of patients of any age (2). Young patients with heart failure often have minor ECG abnormalities in the absence of major ECG abnormalities. The index of suspicion of heart failure in young symptomatic patients should be high even in the absence of major ECG.

**REFERENCES**

**017 MICROVOLT T-WAVE ALTERNANS (MTWA) TESTING IN “REAL WORLD” HEART FAILURE (HF): A STUDY OF PREVALENCE AND INCREMENTAL PROGNOSTIC VALUE**

C E Jackson,* 1R C Myles, 1I K Tsorlalis, 1J R Dalzell, 1J P Rocchiccioli, 1J R Rodgers, 1V Bezylk, 1N Greenlaw, 1F Ford, 1C M Petrie, 1S M Cobbe, 1J J V McMurray, 1BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 2Department of Biochemistry, Garvanill General Hospital, Glasgow, UK; 3Glasgow Royal Infirmary, Glasgow, UK; 4Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; 5Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, UK

**Background** Ventricular arrhythmias contribute to the high risk of death in heart failure (HF) and can be treated with an implantable cardioverter-defibrillator (ICD). Microvolt T-wave alternans (MTWA) testing examines beat-to-beat fluctuations in the morphology of the T-wave. Alternans is believed to reflect dynamic instability of repolarisation and to be linked, mechanistically, to ventricular arrhythmias. Observational studies in highly selected populations have suggested that MTWA testing may identify individuals likely to benefit from a primary prevention ICD. The aims of this study were to evaluate the applicability of MTWA testing in an unselected cohort of patients recently hospitalised with HF and determine the prevalence and incremental prognostic value of an abnormal test.

**Methods** Consecutive admissions with confirmed HF (typical clinical findings and BNP>100 pg/ml) were recruited in three hospitals from 1 December 2006 to 12 January 2009. Survivors were invited to attend 1-month post-discharge for MTWA testing (HeartTWave II, Cambridge Heart).

**Results** 648 of 1003 patients recruited returned for MTWA testing (58% males, mean age 70.8 years). 318 patients (49%) were ineligible for MTWA testing due to atrial fibrillation (AF), pacemaker-dependency or inability to exercise. Of the 330 patients who underwent MTWA treadmill testing, 100 (30%) were positive, 78 (24%) were negative and 152 (46%) were indeterminate. Failure to achieve the target heart rate due to chronotropic incompetence, secondary to β-blocker therapy or physical limitations, accounted for 75% of indeterminate tests. 131 deaths occurred during a mean follow-up of 18 months. 25% of ineligible patients died vs 17% of eligible patients; 12%, 20% and 19% of patients with a positive, negative and indeterminate test, respectively, died (p=0.24). MTWA results were analysed in the accepted way of non-negative (positive and indeterminate) and negative, but there was still no difference in mortality between the groups (p=0.39). MTWA showed no incremental prognostic value in a multivariable mortality model. The independent predictors of mortality were: lower body mass index (HR 0.96 [95% CI 0.93 to 0.99], p=0.01), New York Heart Association class III–IV (1.72 [95% CI 1.2 to 2.47], p=0.003), previous myocardial infarction (1.68 [95% CI 1.18 to 2.4], p=0.004), elevated B-type natriuretic peptide concentration (1.36 [95% CI 1.12 to 1.65], p=0.002) and elevated troponin (1.57 [95% CI 1.04 to 2.57], p=0.03).

**Conclusion** MTWA treadmill-testing was not widely applicable in typical patients with HF and failed to predict mortality risk. At present MTWA cannot be endorsed as a tool for improving risk stratification in HF.

**018 THE BREAST CANCER, EARLY DISEASE: TOXICITY FROM THERAPY WITH EPIRUBICIN REGIMENS’ C CARDIAC ASSESSMENT AND RISK EVALUATION (BETTER-CARE), CARDIOVASCULAR MAGNETIC RESONANCE (CMR) SUB-STUDY: CYCLE 1 CHANGES PREDICT LATE ANTHRACYCLINE CARDIOTOXICITY**

G C Smith,* 1P Kotwinski, 2J Sanders, 2J Cooper, 1L Ma, 1A Jones, 1M G Mythen, 2H E Montgomery, 2J D Pennell. 1Royal Brompton Hospital, London, UK; 2University College London, London, UK, 3Royal Free Hospital, London, UK; 4University College London and University College London Hospitals, London, UK

**Introduction** A growing number of patients are at risk from chronic anthracycline cardiotoxicity (CAC) as a result of improving prognosis of cancer. This is true even at low, adjuvant doses. In breast